HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
App aims to boost breast cancer treatment adherence in real-world study
Disease control Recruiting nowThis study looks at whether using a mobile app helps people with HR+ HER2- stage II or III breast cancer stick to their prescribed ribociclib and aromatase inhibitor therapy for a full year. The app provides reminders and information about side effects and relapse risks. About 24…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to boost immune response in hard-to-treat breast cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy for breast cancer shows promise in early trial
Disease control Recruiting nowThis early-phase study is testing whether giving radiation therapy together with two drugs (abemaciclib and letrozole) before surgery is safe and doable for people with a common type of early-stage breast cancer (HR+/HER2-). About 15 participants will receive this combination to …
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Mridula George, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New study aims to decode BRCA breast cancer biology for smarter treatment
Knowledge-focused Recruiting nowThis observational study will analyze tumor tissue from 100 people with BRCA1 or BRCA2 mutations and HR-positive, HER2-negative breast cancer. Researchers want to see if different molecular subtypes are linked to how well patients respond to hormone therapy or CDK4/6 inhibitors. …
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Sponsor: Angela Toss • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Sugar tracking study aims to unlock breast Cancer's fuel secrets
Knowledge-focused Recruiting nowThis pilot study looks at how hormone receptor positive/HER2 negative breast cancer uses glucose and other nutrients for energy. Sixteen participants with early-stage breast cancer will receive a special labeled sugar infusion before surgery. Researchers will then analyze tumor a…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Can we predict breast cancer resistance to hormone therapy?
Knowledge-focused Recruiting nowThis study looks at why some hormone-receptor-positive breast cancers stop responding to hormone therapy. About 100 women with early-stage breast cancer will receive standard hormone treatment for 4-12 weeks before surgery. Researchers will analyze tumor samples to find changes i…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC